Trial
NCT02291614
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
MedImmune LLC
Condition
GI Adenocarcinoma
Intervention
AMG 211
Why stopped
The study was terminated because of immunogenicity and business decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-16